Association between the Lung Immune Prognostic Index and mortality in patients with idiopathic inflammatory myopathy-associated interstitial lung disease

Abstract

Objective: To explore the association between the Lung Immune Prognostic Index (LIPI) and 1-year all-cause mortality in patients with idiopathic inflammatory myopathy related interstitial lung disease (IIM-ILD).

Methods: Patients who were diagnosed with IIM-ILD at West China Hospital, Sichuan University from January 2008 to December 2021 were retrospectively included and categorized into three groups based on LIPI. Univariable and multivariable Cox proportional hazards models were conducted to explore potential association between the LIPI and patients' mortality.

Results: A total of 1116 patients were screened, and 830 were included in this study. The multivariable Cox analysis showed that, compared with patients with poor LIPI, the hazard ratio (HR) for all-cause 1-year mortality was 0.22 (95% CI 0.05-0.93, P=0.04) for patients in the good LIPI group (LDH<250 IU/L and dNLR<3). After excluding patients lost to follow-up within one year, a similar result was found for LIPI (HR 0.20, 95% CI 0.05-0.86; P=0.03).

Conclusions: Good LIPI was independently associated with decreased risk of all-cause 1-year mortality in patients with IIM-ILD. This easy-to-obtain index might be served as a potential marker for assessing the prognosis of IIM-ILD.

Keywords

Idiopathic inflammatory myopathy / Interstitial lung disease / Lung Immune Prognostic index / All-cause mortality

References

[1] Vencovsky J, Alexanderson H, Lundberg IE. Idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2019; 45(4): 569-581.

[2] Fathi M, Vikgren J, Boijsen M, Tylen U, Jorfeldt L, Tornling G, et al. Interstitial lung disease in polymyositis and dermatomyositis: Longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008; 59(5): 677-685.

[3] Lundberg IE, de Visser M, Werth VP. Classification of myositis. Nat Rev Rheumatol 2018; 14(5): 269-278.

[4] Mezquita L, Auclin E, Ferrara R, Charrier M, Remon J, Planchard D, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer. JAMA Oncol 2018; 4(3): 351-357.

[5] He X, Wang Y, Ye Q, Wang Y, Min L, Luo Y, et al. Lung immune prognostic index could predict metastasis in patients with osteosarcoma. Front Surg 2022; 9: 923427.

[6] Araki T, Tateishi K, Komatsu M, Sonehara K, Kanda S, Hanaoka M, et al. Association of lung immune prognostic index with survival outcome in advanced thymic carcinoma patients treated with palliative intent chemotherapy. Thorac Cancer 2022; 13(7): 1006-1013.

[7] Sun B, Hou Q, Liang Y, Xue S, Yao N, Wei L, et al. Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer. BMC Cancer 2022; 22(1): 1233.

[8] Sonehara K, Tateishi K, Komatsu M, Yamamoto H, Hanaoka M. Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer. Thorac Cancer 2020; 11(6): 1578-1586.

[9] Li R, Zhu WJ, Wang F, Tang X, Luo F. AST/ALT ratio as a predictor of mortality and exacerbations of PM/DM-ILD in 1 year-a retrospective cohort study with 522 cases. Arthritis Res Ther 2020; 22(1): 202.

[10] Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292(7): 344-347.

[11] Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord 2004; 14(5): 337-345.

[12] Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018; 198(5): e44-e68.

[13] Hatabu H, Hunninghake GM, Richeldi L, Brown KK, Wells AU, Remy-Jardin M, et al. Interstitial lung abnormalities detected incidentally on CT: A position paper from the fleischner society. Lancet Respir Med 2020; 8(7): 726-737.

[14] Chen H, Liu H, Lyu W, Liu Y, Huang M, Zhang Y, et al. An observational study of clinical recurrence in patients with interstitial lung disease related to the antisynthetase syndrome. Clin Rheumatol 2023; 42(3): 711-720.

[15] Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers 2021; 7(1): 86.

[16] Li S, Sun Y, Shao C, Huang H, Wang Q, Xu K, et al. Prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease: A retrospective study of 679 adult cases. Rheumatology (Oxford) 2021; 60(3): 1195-1204.

[17] Johnson C, Pinal-Fernandez I, Parikh R, Paik J, Albayda J, Mammen AL, et al. Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease. Lung 2016; 194(5): 733-737.

[18] Yanagihara T, Inoue Y. Insights into pathogenesis and clinical implications in myositis-associated interstitial lung diseases. Curr Opin Pulm Med 2020; 26(5): 507-517.